Vertex Pharmaceuticals 8-K

Summary

Q3 2026 results and raised FY2026 guidance. Continued cystic fibrosis demand, including ALYFTREK uptake, and growth from newer medicines drove revenue growth; Crinetics-related costs and investment in pipeline and commercial launches weighed on GAAP earnings.

Vertex raised FY2026 revenue guidance to $13.15B-$13.25B and increased its outlook for combined research and development, acquired in-process research and development, and selling, general and administrative expenses, primarily reflecting Crinetics operations and integration.

Key Figures

• Cystic fibrosis product revenue was $3.27B, up 8% Y/Y; ALYFTREK revenue was $706M vs $247M a year earlier, while TRIKAFTA/KAFTRIO revenue was $2.44B vs $2.65B. CASGEVY, a gene-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $99M; JOURNAVX, an oral non-opioid acute-pain medicine, generated $58M, with more than 750,000 prescriptions filled in the quarter.
• Crinetics, whose acquisition established Vertex’s rare-endocrine franchise, was acquired for approximately $10.0B in total equity value, or $9.0B net of cash, cash equivalents and marketable securities acquired. Acquisition-related costs of $502M contributed to the GAAP/non-GAAP earnings difference.
• Cash, cash equivalents and marketable securities totaled $9.8B at 9/30/2026, vs $12.3B at 12/31/2025; Vertex cited $9.0B of net cash used for the Crinetics acquisition and share repurchases, partly offset by $4.5B borrowed under a term loan and operating cash flow. Shares outstanding were 253.5M vs 254.0M at year-end 2025.

Guidance

The revenue outlook includes expectations for continued cystic fibrosis growth and at least $500M combined from CASGEVY and JOURNAVX. Expense guidance includes approximately $100M of acquired in-process research and development expenses; the GAAP/non-GAAP difference primarily reflects $650M-$700M of stock-based compensation and approximately $500M of Crinetics-related compensation and transaction costs.

Guidance changes, derived from earlier filings

Metric	Period	Earlier guidance	Guidance now	Change
Total revenue	FY2026	$13.1B-$13.2B; ≈150 bp Y/Y growth benefit from foreign exchange, net of hedging	$13.15B-$13.25B	raised
Legacy non-CF product revenue (CASGEVY and JOURNAVX)	FY2026	$0.5B or greater	$500M or greater	reaffirmed
Combined GAAP research and development, acquired in-process research and development, and selling, general and administrative expenses	FY2026	$6.3B-$6.45B	$7.15B-$7.2B	raised
Combined non-GAAP research and development, acquired in-process research and development, and selling, general and administrative expenses	FY2026	$5.65B-$5.75B	≈$6.0B	raised
Non-GAAP effective tax rate	FY2026	19.5%-20.5%	19.5%-20.5%	reaffirmed

Investor Takeaways

• The FDA’s 11/30/2026 target action date for povetacicept in IgA nephropathy is the next key decision for Vertex’s potential fifth commercial franchise.
• JOURNAVX prescription growth and its continuing launch are key tests of the newer pain franchise; Vertex reported more than 750,000 prescriptions in Q3 and plans to complete enrollment in its Phase 3 diabetic peripheral neuropathy studies by year-end 2026, with results expected in mid-2027.
• Vertex expects to begin European PALSONIFY launches in H2 2027; continued uptake following its U.S. launch, where approximately 500 of 3,200 target endocrinologists were prescribing by quarter-end, will indicate whether the acquired rare-endocrine business is gaining traction.